An Observastional study of Avastin (Bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer and locally advanced or metastatic non-small cell lung cancer (excluding predominant squamous cell histology) (ARIES)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/3005
• EU PAS number:
  EUPAS3004
• Study ID:
  3005
• Official title and acronym:
  An Observastional study of Avastin (Bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer and locally advanced or metastatic non-small cell lung cancer (excluding predominant squamous cell histology) (ARIES)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC, locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in combination with first-line chemotherapy. Second-line metastatic CRC patients are also eligible. Patients who started their Avastin containing therapy <3 months prior to enrollment are eligible.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Genentech

Study timelines

Date when funding contract was signed

Actual: 05/09/2006

Study start date

Actual: 10/11/2006

Date of final study report

Planned: 31/01/2013

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Genentech, Inc.

Regulatory

• Was the study required by a regulatory body?:
  No